207 related articles for article (PubMed ID: 12375414)
1. Beyond the lab in biotech. With so many drugs in trial, new jobs are opening up.
Carmichael M
Newsweek; 2002 Sep; 140(13):53. PubMed ID: 12375414
[No Abstract] [Full Text] [Related]
2. Trials and error.
Jacobs T
Nat Biotechnol; 2005 Dec; 23(12):1481. PubMed ID: 16333284
[No Abstract] [Full Text] [Related]
3. Rising costs hold up drug discovery.
Miller HI
Nature; 1998 Oct; 395(6705):835. PubMed ID: 9804407
[No Abstract] [Full Text] [Related]
4. Biotech bonanza.
Stipp D
Fortune; 1999 Nov; 140(9):333-4. PubMed ID: 10623111
[No Abstract] [Full Text] [Related]
5. Spinning the wheel on ImClone.
Varchaver N
Fortune; 2003 Apr; 147(8):123-5. PubMed ID: 12728651
[No Abstract] [Full Text] [Related]
6. How changes in drug-safety regulations affect the way drug and biotech companies invest in innovation.
Reed SD; Califf RM; Schulman KA
Health Aff (Millwood); 2006; 25(5):1309-17. PubMed ID: 16966727
[TBL] [Abstract][Full Text] [Related]
7. Investing in risk management.
Fiscus PW
Nat Biotechnol; 1997 Jan; 15(1):88-9. PubMed ID: 9035113
[No Abstract] [Full Text] [Related]
8. Biotech industry struggles with generics approval.
Knight J
Nature; 2004 Jun; 429(6992):588. PubMed ID: 15190316
[No Abstract] [Full Text] [Related]
9. How FDA approves biotechnology drugs.
Manuel SM; Piascik P
Am Pharm; 1995 May; NS35(5):14-5. PubMed ID: 7611131
[No Abstract] [Full Text] [Related]
10. Monoclonal antibody successes in the clinic.
Reichert JM; Rosensweig CJ; Faden LB; Dewitz MC
Nat Biotechnol; 2005 Sep; 23(9):1073-8. PubMed ID: 16151394
[TBL] [Abstract][Full Text] [Related]
11. Biotech's next big blowup?
Stires D
Fortune; 2002 Mar; 145(6):154. PubMed ID: 11913033
[No Abstract] [Full Text] [Related]
12. Biotech jostles with pharma for slice of HIV market.
Katsnelson A
Nat Biotechnol; 2006 Jan; 24(1):3-4. PubMed ID: 16404375
[No Abstract] [Full Text] [Related]
13. Biotech unruffled by setbacks.
Glaser V
Nat Biotechnol; 1997 Jul; 15(7):610-1. PubMed ID: 9219254
[No Abstract] [Full Text] [Related]
14. The drug approval process at the Food and Drug Administration. New biotechnology as a paradigm of a science-based activist approach.
Miller HI; Young FE
Arch Intern Med; 1989 Mar; 149(3):655-7. PubMed ID: 2645844
[No Abstract] [Full Text] [Related]
15. Maine law requires drug companies to provide clinical trial data.
Appell D
J Natl Cancer Inst; 2005 Sep; 97(17):1246. PubMed ID: 16145043
[No Abstract] [Full Text] [Related]
16. How pharmacogenomics will impact the federal regulation of clinical trials and the new drug approval process.
Binzak BA
Food Drug Law J; 2003; 58(1):103-27. PubMed ID: 12739592
[No Abstract] [Full Text] [Related]
17. Is the drought over for pharming?
Kaiser J
Science; 2008 Apr; 320(5875):473-5. PubMed ID: 18436771
[No Abstract] [Full Text] [Related]
18. New clinical trials policy at FDA.
Vastag B
Nat Biotechnol; 2006 Sep; 24(9):1043. PubMed ID: 16964196
[No Abstract] [Full Text] [Related]
19. Pediatric drug development in anesthesiology: an FDA perspective.
Schultheis LW; Mathis LL; Roca RA; Simone AF; Hertz SH; Rappaport BA
Anesth Analg; 2006 Jul; 103(1):49-51. PubMed ID: 16790624
[No Abstract] [Full Text] [Related]
20. Moving goalposts--regulatory oversight of antibacterial drugs.
Brenner R; Ellis-Grosse EJ; Echols R
Nat Biotechnol; 2006 Dec; 24(12):1515-20. PubMed ID: 17160053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
